Artificial Intelligence in Diabetes Management Market to Grow with a CAGR of 8.69% through 2030
Rising Continuous Glucose Monitoring (CGM) is expected
to drive Global Artificial Intelligence in Diabetes Management Market growth in
the forecast period, 2026-2030.
According to TechSci Research report, “Artificial
Intelligence in Diabetes Management Market – Global Industry Size, Share,
Trends, Competition, Forecast & Opportunities, 2020-2030F”, the Global
Artificial Intelligence in Diabetes Management Market stood at USD 13.62
Billion in 2024 and is expected to reach USD 19.03 Billion by 2030 with a CAGR
of 8.69% during the forecast period.
The continuous glucose monitoring (CGM) market is on
the cusp of transformative advancements, driven by the integration of
artificial intelligence (AI). CGM devices have already revolutionized diabetes
management by providing patients with real-time glucose data, allowing them to
monitor their blood sugar levels consistently throughout the day. However, when
AI technology is integrated with CGMs, these devices are set to become
exponentially more effective, enhancing both the accuracy and the insights they
offer. AI-powered algorithms will be able to analyze the glucose data in
real-time, identifying patterns and predicting potential risks such as
hypoglycemia or hyperglycemia before they become critical. This predictive
capability will provide early alerts, allowing patients to take proactive
measures—whether adjusting their insulin intake or modifying their diet or
exercise routines—well before experiencing a dangerous drop or spike in glucose
levels.
Beyond predictive analytics, AI integration will
enhance the reliability of CGM systems by identifying and correcting anomalies,
such as sensor calibration errors, which could lead to inaccurate glucose
readings. This continuous quality control ensures that the data collected is as
accurate as possible, giving patients more confidence in the device. The AI
system will also reduce the cognitive load on patients by processing large
amounts of complex data and making actionable recommendations based on individual
patient needs. This means that users can focus on following through with
lifestyle adjustments rather than spending time analyzing raw glucose data.
The integration of AI in CGMs will result
in more personalized care. AI systems will tailor glucose-related alerts and
recommendations according to the patient's specific health profile, ensuring
that their treatment plan remains highly customized and adaptive. The growing
prevalence of mobile apps and cloud-based platforms will allow AI-enhanced CGMs
to seamlessly transmit glucose data to healthcare providers, enabling real-time
collaboration and quicker decision-making. With these advancements, CGMs will
become indispensable tools in diabetes management, providing unparalleled
precision, convenience, and the ability to better manage the condition.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Artificial Intelligence in Diabetes Management Market”
The Global Artificial Intelligence in Diabetes
Management Market is segmented into device, technique, regional distribution,
and company.
Based on device, Glucose monitoring devices are set to be the fastest-growing segment in the Global Artificial Intelligence in Diabetes Management Market during the forecast period. This growth is driven by several factors. First, the increasing global prevalence of diabetes has heightened the need for advanced management tools. The integration of AI into glucose monitoring devices has significantly improved their accuracy, real-time data analysis, and personalized treatment options. Additionally, the rising adoption of wearable and IoT-based healthcare technologies has made continuous glucose monitoring more accessible and convenient. Consequently, these devices are expected to be a key driver in shaping the future of diabetes management, positioning them as a leading force in the market's growth..
Based on region, The second most dominating
region in the Artificial Intelligence in Diabetes Management Market was Europe.
The region’s strong healthcare infrastructure, coupled with a growing awareness
of diabetes management technologies, contributes to its significant market
share. Countries such as Germany, the United Kingdom, and France are leading
the way in AI-driven diabetes solutions, with widespread adoption of advanced
diagnostic tools, insulin delivery systems, and glucose monitoring devices.
Europe’s
regulatory landscape also plays a crucial role in supporting the growth of AI
in diabetes management. The European Medicines Agency (EMA) has been proactive
in ensuring the approval of innovative medical devices, including AI-powered
systems, providing a clear pathway for market entry. This regulatory support
has boosted confidence among healthcare providers and device manufacturers,
driving further market expansion. Europe’s aging population is contributing to the rising prevalence of diabetes,
which in turn increases the demand for more efficient management solutions. The
European healthcare system's emphasis on personalized medicine and chronic
disease management further accelerates the adoption of AI technologies for
diabetes care.
Collaboration
between tech companies and healthcare providers, along with increasing
investments in AI research, is another factor propelling the growth of the
market. The adoption of AI-enabled diabetes management devices in both urban
and rural healthcare settings is gradually becoming more common, creating a
robust market environment in Europe. This positions the region as a strong
second in the global rankings for AI in diabetes management.
Major companies operating in Global Artificial
Intelligence in Diabetes Management Market are:
- Vodafone
Group PLC
- Apple
Inc
- Google
Inc
- International
Business Machines Corporation (IBM)
- Glooko
Inc
- Tidepool
Inc
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“Enhanced personalization is rapidly becoming one of
the most significant trends in diabetes care, driven by the increasing
capabilities of AI technologies. Personalized medicine has long been a goal in
healthcare, but advancements in AI and data analytics are now making it a
reality in diabetes management. AI’s ability to analyze vast amounts of
individual patient data—such as medical histories, genetic predispositions,
current health status, and lifestyle factors—allows for the creation of highly
personalized treatment plans. These plans are not static but can evolve in
real-time, adapting to changes in a patient’s condition, behavior, and external
factors like stress levels or dietary habits. This dynamic approach provides a
more responsive and tailored treatment experience. For example, AI-powered
algorithms can suggest adjustments to insulin dosages based on real-time blood
glucose data or recommend dietary changes based on a patient’s activity level
and metabolic response. Over time, AI systems can learn from each patient's
responses to various treatments, further refining the personalization of their
care. This continuous feedback loop leads to more precise and effective
management strategies that are individualized, rather than relying on
generalized treatment protocols. As AI continues to advance, the potential for
even more sophisticated personalization is enormous, offering patients a level
of care that is responsive, predictive, and adaptive. Personalized
diabetes care through AI not only aims to improve clinical outcomes but also
enhances patient engagement by giving them a more active role in their
treatment plan, improving their adherence to prescribed therapies and lifestyle
recommendations”, said Mr. Karan Chechi, Research Director of TechSci Research,
a research-based management consulting firm.
“Artificial
Intelligence in Diabetes Management Market Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Device (Diagnostic Devices, Glucose
Monitoring Devices, Insulin Delivery Devices), By Technique (Case-Based
Reasoning, Intelligent Data Analysis), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Artificial Intelligence in Diabetes Management Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Artificial Intelligence in Diabetes Management Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com